Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus
Joan T Merrill, Ellen M Ginzler, Daniel J Wallace, James D McKay, Jeffrey R Lisse, Cynthia Aranow, Frank R Wellborne, Michael Burnette, John Condemi, Z John Zhong, Lilia Pineda, Jerry Klein, William W Freimuth, LBSL02/99 Study Group, Joan T Merrill, Ellen M Ginzler, Daniel J Wallace, James D McKay, Jeffrey R Lisse, Cynthia Aranow, Frank R Wellborne, Michael Burnette, John Condemi, Z John Zhong, Lilia Pineda, Jerry Klein, William W Freimuth, LBSL02/99 Study Group
Abstract
Objective: To evaluate the safety profile of long-term belimumab therapy combined with standard therapy for systemic lupus erythematosus (SLE) in patients with active disease.
Methods: Patients who were randomized to receive intravenous placebo or belimumab 1, 4, or 10 mg/kg, plus standard therapy, and completed the initial 52-week double-blind treatment period were then allowed to enter a 24-week open-label extension phase. During the extension period, patients in the belimumab group either received the same dose or were switched to 10 mg/kg and patients in the placebo group were switched to belimumab 10 mg/kg. Patients who achieved a satisfactory response during the 24-week extension period were allowed to participate in the long-term continuation study of monthly belimumab 10 mg/kg. Adverse events (AEs) and abnormal laboratory results were analyzed per 100 patient-years in 1-year intervals.
Results: Of the 364 patients who completed the 52-week double-blind treatment period, 345 entered the 24-week extension, and 296 continued treatment with belimumab in the long-term continuation study. Safety data through 4 years of belimumab exposure (1,165 cumulative patient-years) are reported. Incidence rates of AEs, severe/serious AEs, infusion reactions, infections, malignancies, grades 3/4 laboratory abnormalities, and discontinuations due to AEs were stable or declined during 4-year belimumab exposure. The most common AEs included arthralgia, upper respiratory tract infection, headache, fatigue, and nausea. Serious infusion reactions were rare: only 1 occurred during the 4-year followup period. Rates of serious infection decreased from 5.9/100 patient-years to 3.4/100 patient-years, and no specific type of infection predominated.
Conclusion: Belimumab added to standard therapy was generally well-tolerated over the 4-year treatment period in patients with SLE, which suggests that belimumab can be administered long term with an acceptable safety profile.
Trial registration: ClinicalTrials.gov NCT00071487 NCT00583362.
Copyright © 2012 by the American College of Rheumatology.
Source: PubMed